Abstract:Cholangiopathies are defined as focal or extensive damage of the bile ducts. According to the pathogenetic mechanism, it may be immune-mediated or due to genetic, infectious, toxic, vascular, and obstructive causes. Their chronic evolution is characterized by inflammation, obstruction of bile flow, cholangiocyte proliferation, and progression toward fibrosis and cirrhosis. Immune-mediated cholangiopathies comprise primary sclerosing cholangitis (PSC), autoimmune cholangitis and IgG4-associated cholangitis in adults and biliary atresia (BA), neonatal sclerosing cholangitis (NSC) in children. The main purpose of this narrative review was to highlight the similarities and differences among immune-mediated cholangiopathies, especially those frequent in children in which cholangiocyte senescence plays a key role (BA, NSC, and PSC). These three entities have many similarities in terms of clinical and histopathological manifestations, and the distinction between them can be hard to achieve. In BA, bile duct destruction occurs due to aggression of the biliary cells due to viral infections or toxins during the intrauterine period or immediately after birth. The consequence is the activation of the immune system leading to severe inflammation and fibrosis of the extrahepatic biliary tract, lumen stenosis, and impairment of the biliary flow. PSC is characterized by inflammation and fibrosis of intra- and extrahepatic bile ducts, leading to secondary biliary cirrhosis. It is a multifactorial disease that occurs because of genetic predisposition [human leukocyte antigen (HLA) and non-HLA haplotypes], autoimmunity (cellular immune response, autoantibodies, association with inflammatory bowel disease), environmental factors (infections or toxic bile), and host factors (intestinal microbiota). NSC seems to be a distinct subgroup of childhood PSC that appears due to the interaction between genetic predisposition (HLA B8 and DR3) and the disruption of the immune system, validated by elevated IgG levels or specific antibodies [antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA)]. Currently, the exact mechanism of immune cholangiopathy is not fully understood, and further data are required to identify individuals at high risk of developing these conditions. A better understanding of the immune mechanisms and pathophysiology of BA, NSC, and PSC will open new perspectives for future treatments and better methods of preventing severe evolution.

Immune remodulation in pediatric inherited metabolic liver diseases

Navigating Immune Cell Immunometabolism after Liver Transplantation

Therapeutic and tampering approaches for mitochondrial associated diseases

Targeting the Hepatic Microenvironment to Improve Ischemia/Reperfusion Injury: New Insights into the Immune and Metabolic Compartments

Focus on Diagnosis and Treatment of Genetic Liver Disorders

Role of Innate Immunity in Pediatric Post-transplant Idiopathic Liver Fibrosis

The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases

Interorgan communication with the liver: novel mechanisms and therapeutic targets

Mitochondrial Dysfunction: A Promising Therapeutic Target for Liver Diseases

Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus

The immunological and metabolic landscape in primary and metastatic liver cancer

Metabolic Reprogramming in Immune Response and Tissue Inflammation

Complex Interplay Between the Immune System, Metabolism, and Epigenetic Factors in Autoimmune Liver Diseases

Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications

Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer

Immune-mediated cholangiopathies in children: the need to better understand the pathophysiology for finding the future possible treatment targets

Metabolic regulation of the immune system in health and diseases: mechanisms and interventions

The Gut–Liver Axis in Pediatric Liver Health and Disease

Inherited disorders of complex lipid metabolism: A clinical review

Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases